Genmab — Juli 2019

[bikube]

JnJ giver 0,95$ i udbytte iflg. SA.

[E_L]

the other one is GEN1042, which disappeared from clinicaltrials a few weeks ago

[E_L]

and we just had this message last month https://biontech.de/2019/06/17/biontech-and-genmab-initiate-first-in-human-phase-i-iia-trial-of-bispecific-antibody-duobody-pd-l1x4-1bb-in-solid-tumors/

[AaBforever]

Mener det er 12.45.

[AaBforever]

Det er kl. 12.45 i morgen.

[Solsen]

Are GEN1042 the CD40x4-1BB duobody ?

[Solsen]

Sorry havent seen Peter12...

[Solsen]

https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003716-47/DK Someone has looked at the trial july 2. Se at the end.

[royal]

Favourable

[E_L]

@Solsen yes

[peter12]

But could ethics commite have used another word ?

[peter12]

Jo eller passed

[Solsen]

Seems they dropped the trial as Genmab dont have it in the pipeline any more.

[Solsen]

Not that I have expected anything from it.

[Solsen]

DR5/DR5 and CD20/CD3 ar much more important. Especially the hexabody DR5 are very exciting as its look like the hexabody technology could belong to the future.

[Plimsoller]

Hvornår forventer vi resultater fra dem?

[Solsen]

I dette halvår får vi de første data.

[Solsen]

De to nævnte programmer er der chance for bliver udliciteret, idet JW har oplyst, at potentialet er for stort at løfte for Genmab alene.

[Plimsoller]

Tak Solsen. Måske et dumt spørgsmål, men kunne størstedelen af emissionen ikke tænkes at skulle trække de to programmer lidt længere i Genmab regi end de ellers ville kunne? Eller rækker den sum ikke langt i den forbindelse?

[Solsen]

Lader ikke til, at det er i dag de kører book building på de nye aktierne. Er sats at gennemføre efter salgstallene.